Scientific Industries, Inc. reported net revenues of $2,329,900 for the second quarter ended June 30, 2025, a 12.0% decrease from $2,647,300 in the prior year period. The company posted a net loss of $1,522,700, or $(0.13) diluted earnings per share, compared to a net loss of $1,283,600, or $(0.12) diluted earnings per share, in the same period of 2024.
Despite the overall revenue decline, the Torbal division's sales increased by 11%, driven by growing demand for VIVID products. The Bioprocessing Systems Operations recorded lower sales for the quarter but ended with a record number of leads and pipeline value, with deal closings anticipated in the second half of 2025.
The company highlighted the successful divestiture of its legacy Genie business for approximately $10 million, positioning it for sustainable growth in pharmacy and pharmaceutical industries. Scientific Bioprocessing supported fifteen external projects for its MPS DOTS system, including field trials with two of the largest biotech companies for mammalian cell monitoring, and gained sixteen new customer accounts for MPS systems.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.